Whalesbook
Market Ne Diya Thanda Response
Max Healthcare Institute ke share mein aaj lagbhag 6% ki giraawat dekhi gayi. Quarter ending March 31, 2026 ke liye company ne ₹387 Crore ka Net Profit report kiya, jo pichle saal ke comparison mein 3% zyada hai. Wahi, gross revenue 10% badhkar ₹2,664 Crore ho gaya. Investors ka dhyan margin pressure par tha, jisne operational performance ko overshadow kar diya.
Operational metrics bhi theek-thaak rahe, jaise ki bed occupancy rate 75% raha aur occupied bed days 8% badhe. Average revenue per occupied bed bhi thoda badhkar ₹77,900 ho gaya.
Full-Year Performance Aur Bade Investments
Fiscal year 2026 ke liye, Max Healthcare ne network gross revenue ₹10,538 Crore report kiya. Profit after tax mein 22% ka jump dekha gaya, jo ₹1,631 Crore raha (FY25 mein ₹1,336 Crore tha). Board ne FY26 ke liye ₹2 per equity share ka final dividend bhi propose kiya hai.
Sabse badi khabar hai ₹1,400 Crore ka investment Lucknow mein ek naya 712-bed hospital banane ke liye, jo FY30 mein khulega. Isse Uttar Pradesh mein badhti healthcare demand ko pura karne ka aim hai. Ye company ka Lucknow mein doosra facility hoga. Max Healthcare ka market value abhi lagbhag ₹1.06 lakh Crore hai.
Valuation Aur Competition
Max Healthcare ka current P/E ratio lagbhag 69.15x hai, jo iske 10-year median ke paas hai. Kuch analysts is stock ko GF Value™ ₹1,575.75 ke saath undervalued maan rahe hain. Lekin market ki reaction se lagta hai ki investors valuation ke saath profitability ko bhi closely dekh rahe hain.
Iske competitors jaise Apollo Hospitals Enterprise aur Fortis Healthcare bhi isi market mein hain. Dusre hospital stocks jaise Kovai Medical Center and Hospital Ltd. ka P/E 25.6x aur Narayana Hrudayalaya Ltd. ka 48.0x hai, jo Max Healthcare se kam hain.
Margin Pressure Aur Execution Risks
Market ki reaction ek bade concern ko highlight karti hai: margin pressure. Quarter ke liye 3% profit growth, 10% revenue growth se kam tha, matlab costs revenue se zyada tezi se badh rahi hain. Lucknow mein ₹1,400 Crore ka naya hospital, jo FY30 mein start hoga, ek bada long-term financial commitment hai. Bade construction projects mein execution risks, healthcare policy mein changes, ya badhti competition future returns ko affect kar sakte hain. Ek aur baat jo notice ki gayi hai, woh hai promoters ne apni shareholding kam ki hai.
Analyst Ka View
Analysts generally positive hain aur 'Buy' rating de rahe hain. Consensus target price ₹1,208.95 hai, jo 15% se zyada upside ka potential dikhata hai. Company ka strategy organic growth aur acquisitions par focus karta hai, jaise Kalinga Hospital Ltd. mein stake lena. Network ne 20 consecutive quarters se consistent growth dikhaya hai.